The Lepu-backed genetic cancer therapy developer has completed a $94.9m round co-led by CICC Capital, Share Capital, Vertex Ventures China and Qianhai FOF.

Cleva Pharma Capital backed a series C round that will support the clinical progress of drug candidates for sensorineural hearing loss and multiple sclerosis.

Returning backer Novo was among the investors in a series C round for the synthetic cancer treatment developer that was led by RA Capital Management.

The vehicle charging technology developer, which counts Sumitomo, LG Chem, Samsung, Bangchak and Lenovo as investors, has now raised $191m in total.

Swisscom Ventures participated in a round that lifted the total raised by the laboratory simulation software provider to $104m.

The lottery ticket purchasing app provider said it saw record new user growth last month, as it secured funding from investors including Tegna and Circle K.

Boeing HorizonX and SES Engineering both strapped themselves into the satellite technology developer's latest round, bringing its overall funding to about $60m.

UC Davis's probiotics spinout secured an undisclosed amount as Bow Capital backed the first close of a series D round with a $55m target.

Osage University Partners has contributed to an oversubscribed series C round for Cyteir, which was led by RA Capital.

Today's deal net contains news from PGDx, Notch Therapeutics, Quell Therapeutics, SpyBiotech, Vision Medicals, Future Meat Technologies, BusUp and Advanced Chemotherapy Technologies.